Literature DB >> 15472188

Peripheral blood monocyte vitamin D receptor levels are elevated in patients with idiopathic hypercalciuria.

Murray J Favus1, Alexander J Karnauskas, Joan H Parks, Fredric L Coe.   

Abstract

Idiopathic hypercalciuria (IH) is the most common cause of calcium oxalate nephrolithiasis. Increased intestinal calcium absorption and bone resorption and decreased tubule calcium reabsorption may be caused by elevated serum 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] in some patients but not in those with normal serum 1,25(OH)(2)D(3) levels. Because 1,25(OH)(2)D(3) exerts its biological actions through binding to the cellular vitamin D receptor (VDR), the present study was undertaken to test the hypothesis that VDR levels are elevated in IH patients. Ten male IH calcium oxalate stone-formers were paired with controls matched in age within 5 yr and lacking a history of stones or family history of stones. Blood was obtained for serum, peripheral blood monocytes (PBMs) were separated from lymphocytes and other mononuclear cells, and PBM VDR content was measured by Western blotting. The PBM VDR level was 2-fold greater in IH men at 49 +/- 21 vs. 20 +/- 15 fmol/mg protein, mean +/- sd; P < 0.008. Serum 1,25(OH)(2)D(3) levels were not higher than controls (48 +/- 14 vs. 39 +/- 11 pg/ml; P < 0.068). In conclusion, PBM VDR levels are elevated in IH calcium oxalate stone-formers. The elevation could not be ascribed to increased serum 1,25(OH)(2)D(3) levels. These results suggest that the molecular basis for IH involves a pathological elevation of tissue VDR level, which may elevate intestinal calcium absorption and bone resorption and decrease renal tubule calcium reabsorption. The mechanism for increased VDR in IH patients with normal serum 1,25(OH)(2)D(3) levels is unknown.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15472188     DOI: 10.1210/jc.2004-0412

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  29 in total

Review 1.  Bone disease and idiopathic hypercalciuria.

Authors:  Joseph E Zerwekh
Journal:  Semin Nephrol       Date:  2008-03       Impact factor: 5.299

Review 2.  Bone disease and hypercalciuria in children.

Authors:  Joseph E Zerwekh
Journal:  Pediatr Nephrol       Date:  2009-11-03       Impact factor: 3.714

Review 3.  Bone disease in pediatric idiopathic hypercalciuria.

Authors:  Maria Goretti Moreira Guimarães Penido; Marcelo de Sousa Tavares
Journal:  World J Nephrol       Date:  2012-04-06

Review 4.  Kidney stone disease.

Authors:  Fredric L Coe; Andrew Evan; Elaine Worcester
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

5.  Expression of fibroblast growth factor 23, vitamin D receptor, and sclerostin in bone tissue from hypercalciuric stone formers.

Authors:  Viviane Barcellos Menon; Rosa Maria Affonso Moysés; Samirah Abreu Gomes; Aluizio Barbosa de Carvalho; Vanda Jorgetti; Ita Pfeferman Heilberg
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-24       Impact factor: 8.237

Review 6.  Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Authors:  Faryal Mirza; Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

7.  The relation between bone and stone formation.

Authors:  Nancy S Krieger; David A Bushinsky
Journal:  Calcif Tissue Int       Date:  2012-12-18       Impact factor: 4.333

Review 8.  Genetic causes of hypercalciuric nephrolithiasis.

Authors:  Michael J Stechman; Nellie Y Loh; Rajesh V Thakker
Journal:  Pediatr Nephrol       Date:  2008-04-30       Impact factor: 3.714

9.  Persistence of 1,25D-induced hypercalciuria in alendronate-treated genetic hypercalciuric stone-forming rats fed a low-calcium diet.

Authors:  Kevin K Frick; John R Asplin; Christopher D Culbertson; Ignacio Granja; Nancy S Krieger; David A Bushinsky
Journal:  Am J Physiol Renal Physiol       Date:  2014-02-26

Review 10.  New insights into the pathogenesis of idiopathic hypercalciuria.

Authors:  Elaine M Worcester; Fredric L Coe
Journal:  Semin Nephrol       Date:  2008-03       Impact factor: 5.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.